Beauty biotech startup Kokuma has appointed distinguished US dermatologist Dr. Michael H. Gold as its scientific advisor.

In his advisory role, he will help shape Kokuma’s scientific strategy, provide insights grounded in real dermatological patient needs, support clinical development planning, and expand Kokuma’s engagement within the global medical and scientific community.

Kokuma has developed Tonasulike-D, a depigmenting active ingredient said to deliver clinically proven results at a concentration of just 0.01%.

Gold is a globally recognized dermatologist, clinical researcher, and thought leader in aesthetic medicine, bringing more than 30 years of experience guiding innovation across leading global skincare and dermatology brands.

Founder and Medical Director of the Gold Skin Care Centre, Advanced Aesthetics Medical Spa, and the Tennessee Clinical Research Centre, he has established himself as a pioneer in dermatologic research, known for introducing breakthrough technologies into both medical and aesthetic practice.

Gold has authored hundreds of scientific publications, taught extensively around the world, and presented at major international congresses, including IMCAS (International Master Course on Aging Science).

“I’m thrilled to join Kokuma as scientific advisor at such a pivotal moment for the company. Their discovery platform and breakthrough in pigmentation research opens a new chapter for dermatology innovation,” he said.

“The clinical results for Tonasulike-D are particularly compelling and will have meaningful outcomes for both clinicians and patients. I look forward to supporting Kokuma in translating this science into real-world impact.”

Yannick Quesnel, chief scientific officer & co-founder of Kokuma, added: “We are pleased to welcome Dr. Gold as scientific advisor.

“His dermatology expertise complements our biotech and chemistry platform, reinforcing our ability to connect scientific breakthroughs with real-world dermatology and cosmeceutical applications while accelerating our innovation pipeline, at a key moment ahead of this year’s IMCAS.”

‍